Human Anti-NGF Recombinant Antibody (clone E3) (CAT#: HPAB-1889-FY)

Figure 1 Shows a graph comparing the NGF blocking effect of various Fabs in the presence of 0.4 ng/ml human NGF.

Survival of E13.5 mouse trigeminal neurons in various concentrations of Fab E3; murine 911 Fab; and Fab H19-L129 and Fab 8L2-6D5 was assessed.

Figure 2 Shows a graph comparing the NGF blocking effect of various Fabs in the presence of 0.04 ng/ml of rat NGF.

Survival of E13.5 mouse trigeminal neurons in various concentrations of Fab E3; murine Fab 911; and Fab H19-L129 and 8L2-6D5 was assessed.

Figure 3 A graph depicts resting pain assessed 24 hours after surgery.

Ttreatment with 0.02 mg/kg, 0.1 mg/kg, 0.6 mg/kg, or 1 mg/kg of anti-NGF antibody E3 reduced pain.

Figure 4 A graph depicts resting pain assessed 24 hours after surgery.

Treatment with 0.5 mg/kg of anti-NGF antibody E3 significantly (p<0.005) reduced resting pain when injected two hours after surgery.

Figure 5 A graph shows the results of BIAcore analysis of the binding affinity to human NGF of antibody E3 (Fab) (referred to as “3E Fab”).

E3 bound human NGF with a KD of approximately 0.07 nM.

Figure 6 A graph depicts the ability of antibody E3 (solid triangles; referred to as “3E”) to inhibit NGF-dependent survival of E13.5 trigeminal neurons in the presence of human NGF.

Various concentrations (20, 4, 0.8, 0.16, 0.032, 0.0064, 0.00128, and 0.0 nM) of antibody E3 (solid triangles; referred to as "3E"), antibody 911 (solid circles), and a trkA receptor immunoadhesin (shaded squares; referred as "trkA-Fc) to inhibit NGF-dependent survival of E13.5 trigeminal neurons in the presence of 0.4 ng/ml human NGF (saturating conditions).

Figure 7 A graph depicts the anti-NGF antagonist antibody E3 (termed “3E in the figure”) or Fab 911 did not inhibit the neuronal survival promoted by NT3, NT4/5 and MSP, even at antibody concentrations as high as 200 nM.

Various concentrations (20 nM, 2 nM, or 0.2 nM) of E3 Fab (termed "3E" in the figure) and mouse antibody 911 Fab were used in the presence of no added neurotrophin (termed "control"), 400 pM NGF (termed "NGF-400 pM), 10 nM NT3 (termed "NT3-10 nM) or 600 pM MSP (termed "MSP-600 pM).

Figure 8 A graph depicts the anti-NGF antagonist antibody E3 did not inhibit the neuronal survival promoted by NT3, NT4/5 and MSP.

The anti-NGF antagonist antibody E3 (Fab or full antibody) (termed "3E in the figure") or mouse antibody 911 (Fab or at antibody concentrations as high as 200 nM Various concentrations (200 nM and 80 nM) of E3 Fab and full antibody and mouse antibody 911 full antibody and Fab were used in the presence of no added neurotrophins (termed "no factor"), 400 pM NGF (termed "NGF-400 pM), 10 nM NT3 (termed "NT3-10 nM) or 600 pM MSP (termed "MSP-600 pM).

Figure 9 A graph demonstrates the effects of anti-NGF antibodies on body weight in arthritis in rats (rheumatoid arthritis model) after administration of anti-NGF antibodies on D14 and D19.

E3 (1 mg/kg, i.v. on day 14 and day 19), 911 (10 mg/kg, i.v. on day 14 and day 19), or indo (indomethacin 3 mg/kg, p.o. daily over 10 days) were administered to arthritic mice. Body weight values are expressed in grams as mean±s.e.m.